Related Experiment Video
Updated: Sep 6, 2025

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
Published on: July 8, 2025
COVID-19 and Fungal Diseases
Kyoung-Ho Oh1, Seung-Hoon Lee1
1Department of Otorhinolaryngology-Head and Neck Surgery, Korea University Ansan Hospital, Ansan 15355, Korea.
Abstract:
Coronavirus Disease-2019 (COVID-19) can cause secondary bacterial and fungal infections by affecting the expression of pro-inflammatory markers, such as tumor necrosis alpha and certain cytokines, as well as the numbers of CD4 and CD8 cells. In particular, in the head and neck, various fungal species are naturally present, making it the main route of secondary infection. It is difficult to clearly distinguish whether secondary infection is caused by COVID-19 directly or indirectly as a result of the immunocompromised state induced by drugs used to treat the disease. However, the risk of fungal infection is high in patients with severe COVID-19, and lymphopenia is observed in most patients with the disease. Patients with COVID-19 who are immunosuppressed or have other pre-existing comorbidities are at a significantly higher risk of acquiring invasive fungal infections. In order to reduce morbidity and mortality in these patients, early diagnosis is required, and treatment with systemic antifungal drugs or surgical necrotic tissue resection is essential. Therefore, this review aimed to examine the risk of fungal infection in the head and neck of patients with COVID-19 and provide information that could reduce the risk of mortality.
Insights
COVID-19 patients, especially those with severe illness or comorbidities, face a high risk of secondary fungal infections in the head and neck. Early diagnosis and treatment are crucial to reduce mortality.
Area of Science:
- Infectious Diseases
- Immunology
- Otolaryngology
Background:
- COVID-19 impacts immune markers (TNF-alpha, cytokines) and cell counts (CD4, CD8), increasing susceptibility to secondary infections.
- The head and neck region harbors natural fungal species, serving as a primary site for secondary infections.
- Distinguishing COVID-19's direct vs. indirect role in infection due to immunosuppression from treatments is challenging.
Purpose of the Study:
- To review the risk of fungal infections in the head and neck of COVID-19 patients.
- To provide insights for reducing mortality associated with these infections.
Main Methods:
- Literature review focusing on COVID-19's impact on immune status.
- Analysis of risk factors for secondary fungal infections in head and neck cancer patients.
- Examination of diagnostic and treatment strategies for invasive fungal infections.
Main Results:
- Severe COVID-19 and pre-existing comorbidities significantly elevate the risk of invasive fungal infections.
- Lymphopenia is a common finding in COVID-19 patients, indicating immune compromise.
- High risk of fungal infection observed in immunocompromised COVID-19 patients.
Conclusions:
- Early diagnosis and prompt treatment with systemic antifungals or surgical intervention are essential for managing invasive fungal infections in COVID-19 patients.
- Reducing morbidity and mortality requires a proactive approach to identifying and treating fungal co-infections.
- Understanding the interplay between COVID-19, immune status, and fungal infections is critical for patient outcomes.
Related Concept Videos
Fungal Group Zygomycota
Fungal Phylum Microsporidia
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Overview of Fungi
Fungal Phylum Ascomycota
Fungal Phylum Basidiomycota

